Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.34 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 3/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.30 |
| ▸ | MMP13 | P45452 | 2/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP7 | P09237 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533583 | 0.90 | NTRK1 (0.34) | ADRB2NTRK1PORCNGPR119F2 | |
| SCHEMBL533408 | 0.89 | ADRB2 (0.34) | ADRB2NTRK1PORCNGPR119 | |
| SCHEMBL533843 | 0.88 | ADRB2 (0.36) | ADRB2NTRK1PORCNGPR119TDP1 | |
| SCHEMBL533780 | 0.84 | PTGER2 (0.35) | GPR119MEN1KMT2A | |
| SCHEMBL533487 | 0.83 | GPR119 (0.33) | NTRK1GPR119ADAMTS4 | |
| SCHEMBL13571649 | 0.81 | PTGER2 (0.37) | ALDH1A1 | |
| SCHEMBL11023383 | 0.81 | PTGER2 (0.47) | — | |
| SCHEMBL534202 | 0.81 | PTPRB (0.33) | KMT2A | |
| SCHEMBL534306 | 0.80 | PTGER2 (0.33) | ADRB2ALDH1A1 | |
| SCHEMBL535026 | 0.78 | ALOX5AP (0.33) | NTRK1PORCNGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648097-B2 | Pyridylaminoacetic acid compound | UBE INDUSTRIES, LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | UBE INDUSTRIES, LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | F12, C1S, AKR1C3 | ADRB2 373/4885NTRK1 3921/4885PORCN 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.